Home LiteratureArticle Details
PMID: 12759283 Published · ppublish English Journal Article Review

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

Annals of the rheumatic diseases ·Vol. 62 ·No. 6 ·2003-06-00 ·Pages 501-9

Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP

Abstract

Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.

MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use Cyclooxygenase Inhibitors/therapeutic use Drug Synergism Humans Inflammation/drug therapy,physiopathology Leukotrienes/physiology Lipoxygenase Inhibitors/therapeutic use Prostaglandin-Endoperoxide Synthases/physiology
Chemicals
Anti-Inflammatory Agents, Non-Steroidal Cyclooxygenase Inhibitors Leukotrienes Lipoxygenase Inhibitors Prostaglandin-Endoperoxide Synthases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Martel-Pelletier J
Osteoarthritis Research Unit, Centre hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada. [email protected]
Lajeunesse D
Reboul P
Pelletier J-P
References (90)
90 references, click to expand
  1. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
    Inflamm Res. 2000 Aug;49(8):367-92 PMID: 11028754
  2. COX-2 and the kidneys.
    Curr Pharm Des. 2000 Nov;6(17):1737-53 PMID: 11102561
  3. Cyclooxygenase 2 and the kidney.
    Curr Opin Nephrol Hypertens. 2001 Jan;10(1):89-98 PMID: 11195058
  4. Cyclo-oxygenase products and atherothrombosis.
    Ann Med. 2000 Dec;32 Suppl 1:21-6 PMID: 11209977
  5. Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation?
    Biochem Biophys Res Commun. 2001 May 25;283(5):1003-6 PMID: 11355871
  6. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways.
    J Clin Invest. 2001 Jun;107(12):1481-9 PMID: 11413151
  7. Lipid mediator class switching during acute inflammation: signals in resolution.
    Nat Immunol. 2001 Jul;2(7):612-9 PMID: 11429545
  8. The coxibs, selective inhibitors of cyclooxygenase-2.
    N Engl J Med. 2001 Aug 9;345(6):433-42 PMID: 11496855
  9. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy.
    FASEB J. 2001 Sep;15(11):2016-8 PMID: 11511527
  10. Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
    J Rheumatol. 2001 Sep;28(9):2060-5 PMID: 11550975
  11. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.
    Arthritis Rheum. 2001 Oct;44(10):2320-30 PMID: 11665972
  12. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
    Biochem Pharmacol. 2001 Dec 1;62(11):1433-8 PMID: 11728379
  13. Cyclooxygenase-2 inhibitor NS398 preserves neuronal function after hypoxia/ischemia in piglets.
    Neuroreport. 2001 Dec 21;12(18):4065-8 PMID: 11742239
  14. Corneal stimulation of MMP-1, -9 and uPA by platelet-activating factor is mediated by cyclooxygenase-2 metabolites.
    Curr Eye Res. 2001 Aug;23(2):77-85 PMID: 11840344
  15. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines.
    J Rheumatol. 2002 Mar;29(3):546-53 PMID: 11908571
  16. Leukotriene B: a potential mediator of inflammation.
    J Pharm Pharmacol. 1980 Jul;32(7):517-8 PMID: 6105196
  17. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.
    Nature. 1980 Jul 17;286(5770):264-5 PMID: 6250050
  18. Leukotriene B4: an inflammatory mediator in vivo.
    Prostaglandins. 1981 Aug;22(2):213-22 PMID: 6270742
  19. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms.
    Am J Physiol. 1983 Nov;245(5 Pt 1):G601-23 PMID: 6195926
  20. Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C.
    Proc Natl Acad Sci U S A. 1984 May;81(9):2890-2 PMID: 6326150
  21. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice.
    Agents Actions. 1987 Aug;21(3-4):316-9 PMID: 3687587
  22. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes.
    J Biol Chem. 1990 Jan 25;265(3):1436-42 PMID: 2104841
  23. Identification and isolation of a membrane protein necessary for leukotriene production.
    Nature. 1990 Jan 18;343(6255):278-81 PMID: 2300172
  24. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
    Nature. 1990 Jan 18;343(6255):282-4 PMID: 2300173
  25. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit.
    Blood. 1996 Mar 1;87(5):1824-32 PMID: 8634429
  26. Release of leukotriene A4 versus leukotriene B4 from human polymorphonuclear leukocytes.
    J Biol Chem. 1996 Jul 26;271(30):17944-8 PMID: 8663438
  27. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
    Gastroenterology. 1997 Mar;112(3):718-24 PMID: 9041232
  28. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.
    Drugs. 1997 Apr;53(4):563-82 PMID: 9098660
  29. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?
    Prostaglandins. 1997 Feb;53(2):107-37 PMID: 9112289
  30. Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart.
    Br J Pharmacol. 1997 Mar;120(6):1128-34 PMID: 9134226
  31. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.
    J Exp Med. 1997 May 5;185(9):1693-704 PMID: 9151906
  32. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation.
    Prostaglandins Leukot Essent Fatty Acids. 1997 Jun;56(6):417-23 PMID: 9223651
  33. Multiple female reproductive failures in cyclooxygenase 2-deficient mice.
    Cell. 1997 Oct 17;91(2):197-208 PMID: 9346237
  34. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma.
    Thorax. 1997 Nov;52(11):940-5 PMID: 9487340
  35. Leukotrienes: lipid bioeffectors of inflammatory reactions.
    Biochemistry (Mosc). 1998 Jan;63(1):84-92 PMID: 9526099
  36. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats.
    Br J Pharmacol. 1998 Mar;123(5):795-804 PMID: 9535006
  37. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release.
    J Exp Med. 1998 Apr 20;187(8):1285-94 PMID: 9547339
  38. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.
    Gastroenterology. 1998 Jul;115(1):101-9 PMID: 9649464
  39. Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration.
    Inflamm Res. 1998 Oct;47 Suppl 2:S102-6 PMID: 9831331
  40. Expression of cyclo-oxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth.
    Br J Pharmacol. 1998 Nov;125(5):1102-8 PMID: 9846651
  41. 5-Lipoxygenase: a target for antiinflammatory drugs revisited.
    Curr Med Chem. 1999 Jan;6(1):71-85 PMID: 9873115
  42. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
    Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7 PMID: 9874808
  43. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.
    Br J Pharmacol. 1999 Mar;126(5):1200-4 PMID: 10205009
  44. Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta.
    Endocrinology. 1999 Jun;140(6):2685-95 PMID: 10342859
  45. Inducible cyclooxygenase may have anti-inflammatory properties.
    Nat Med. 1999 Jun;5(6):698-701 PMID: 10371510
  46. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action.
    Gastroenterology. 1990 May;98(5 Pt 1):1178-86 PMID: 2157619
  47. Leukotriene B4 potentiates colonic ulceration in the rat.
    Dig Dis Sci. 1990 May;35(5):622-9 PMID: 2158882
  48. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
    J Biol Chem. 1990 Oct 5;265(28):16737-40 PMID: 2120205
  49. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.
    N Engl J Med. 1990 Dec 20;323(25):1745-8 PMID: 1701029
  50. Role of leukotriene C4 in mucosal damage caused by necrotizing agents and indomethacin in the rat stomach.
    Gastroenterology. 1991 Mar;100(3):619-26 PMID: 1993484
  51. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites.
    Kidney Int. 1991 Jan;39(1):95-102 PMID: 1848329
  52. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.
    Am J Gastroenterol. 1992 Mar;87(3):342-6 PMID: 1539569
  53. Designing therapeutically effective 5-lipoxygenase inhibitors.
    Trends Pharmacol Sci. 1992 Aug;13(8):323-30 PMID: 1413091
  54. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    J Rheumatol. 1992 Oct;19(10):1537-41 PMID: 1334515
  55. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs.
    Gut. 1993 Jun;34(6):742-7 PMID: 8390958
  56. Renal complications of nonsteroidal anti-inflammatory drugs.
    Kidney Int. 1993 Sep;44(3):643-53 PMID: 8231040
  57. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage.
    Agents Actions. 1993;39 Spec No:C24-6 PMID: 8273575
  58. Formation of sulphidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit.
    Br J Pharmacol. 1993 Nov;110(3):1206-12 PMID: 8298810
  59. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase.
    Arzneimittelforschung. 1994 May;44(5):629-36 PMID: 8024637
  60. Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl- 2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat.
    Arzneimittelforschung. 1994 Dec;44(12):1329-33 PMID: 7848352
  61. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.
    Arzneimittelforschung. 1995 Jan;45(1):27-32 PMID: 7893265
  62. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury.
    Eur J Pharmacol. 1994 Dec 27;271(2-3):525-31 PMID: 7705453
  63. New insights into the mode of action of anti-inflammatory drugs.
    Inflamm Res. 1995 Jan;44(1):1-10 PMID: 7664022
  64. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.
    Cell. 1995 Nov 3;83(3):483-92 PMID: 8521478
  65. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors.
    J Pharm Pharmacol. 1996 Jan;48(1):46-52 PMID: 8722494
  66. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers.
    J Clin Pharmacol. 1996 May;36(5):462-8 PMID: 8739025
  67. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs.
    Fundam Appl Toxicol. 1996 Sep;33(1):38-48 PMID: 8812216
  68. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2.
    J Biol Chem. 1996 Dec 27;271(52):33157-60 PMID: 8969167
  69. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man.
    Int J Clin Pharmacol Res. 1996;16(1):1-8 PMID: 9001924
  70. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo.
    Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8247-52 PMID: 10393980
  71. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice.
    Inflamm Res. 1999 Aug;48(8):432-6 PMID: 10493160
  72. Effect of pain reduction on postural sway, proprioception, and quadriceps strength in subjects with knee osteoarthritis.
    Ann Rheum Dis. 2002 May;61(5):422-8 PMID: 11959766
  73. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loading.
    Calcif Tissue Int. 2002 Apr;70(4):320-9 PMID: 12004337
  74. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
    Inflamm Res. 2002 Mar;51(3):135-43 PMID: 12005204
  75. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair.
    J Clin Invest. 2002 Jun;109(11):1405-15 PMID: 12045254
  76. Cyclo-oxygenase 2 function is essential for bone fracture healing.
    J Bone Miner Res. 2002 Jun;17(6):963-76 PMID: 12054171
  77. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
    Arthritis Rheum. 2002 Jul;46(7):1804-12 PMID: 12124864
  78. Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.
    J Rheumatol. 2002 Jul;29(7):1446-53 PMID: 12136904
  79. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
    Nat New Biol. 1971 Jun 23;231(25):232-5 PMID: 5284360
  80. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors.
    Am J Med. 1999 Dec 13;107(6A):18S-22S; discussion 22S-26S PMID: 10628590
  81. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development.
    Kidney Int. 2000 Feb;57(2):414-22 PMID: 10652018
  82. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.
    J Immunol. 2000 Mar 1;164(5):2660-6 PMID: 10679106
  83. Constitutive expression of cyclooxygenase-2 (COX-2) in developing brain. A. Choroid plexus in human fetuses.
    Folia Neuropathol. 1999;37(4):287-91 PMID: 10705655
  84. The molecular biology and regulation of 5-lipoxygenase.
    Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 2):S11-5 PMID: 10673219
  85. Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness.
    Circulation. 2000 Mar 28;101(12):1436-40 PMID: 10736289
  86. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
    Arthritis Rheum. 2000 Aug;43(8):1891-6 PMID: 10943882
  87. Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity.
    Ernst Schering Res Found Workshop. 2000;(31):143-85 PMID: 10943332
  88. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
    J Urol. 2000 Sep;164(3 Pt 1):820-5 PMID: 10953162
  89. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
    Cancer Res. 2000 Aug 15;60(16):4629-37 PMID: 10969817
  90. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2.
    J Immunol. 2000 Sep 15;165(6):3402-10 PMID: 10975859
Article Info
Journal
Annals of the rheumatic diseases
Abbr.
Ann Rheum Dis
ISSN
0003-4967
DOI
10.1136/ard.62.6.501
Email
[email protected]
Published
2003-06-00
Pages
501-9
Language
English
Region
England
NLM ID
0372355
PMCID
PMC1754580
Subset
IM
External Links
PubMed source DOI: 10.1136/ard.62.6.501 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2